In vitro responsiveness of human muscle cell peroxisome proliferator-activated receptor δ reflects donors’ insulin sensitivity in vivo
Article first published online: 25 MAY 2011
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation
European Journal of Clinical Investigation
Volume 41, Issue 12, pages 1323–1329, December 2011
How to Cite
Ordelheide, A.-M., Heni, M., Thamer, C., Machicao, F., Fritsche, A., Stefan, N., Häring, H.-U. and Staiger, H. (2011), In vitro responsiveness of human muscle cell peroxisome proliferator-activated receptor δ reflects donors’ insulin sensitivity in vivo. European Journal of Clinical Investigation, 41: 1323–1329. doi: 10.1111/j.1365-2362.2011.02547.x
- Issue published online: 16 NOV 2011
- Article first published online: 25 MAY 2011
- Received 10 December 2010; accepted 19 April 2011
- insulin sensitivity;
- peroxisome proliferator-activated receptor δ;
- skeletal muscle cells
Eur J Clin Invest 2011; 41 (12): 1323–1329
Background Peroxisome proliferator-activated receptor δ (PPARδ) activation enhances muscular fatty acid oxidation and oxidative phosphorylation, and muscle’s oxidative capacity positively associates with whole-body insulin sensitivity. Therefore, we asked here whether human muscle cell PPARD expression is a determinant of donors’ insulin sensitivity.
Materials and methods Skeletal muscle cells derived from 38 nondiabetic donors were differentiated in vitro to myotubes, and gene (mRNA) expression was quantified by real-time RT–PCR. Donors’ insulin sensitivity was calculated from plasma insulin and glucose levels during oral glucose tolerance test (OGTT) and hyperinsulinemic-euglycemic clamp.
Results Basal myotube PPARD expression was closely related to the expression of its target genes PDK4 and ANGPTL4 (P = 0·0312 and P = 0·0003, respectively). Basal PPARD, PDK4 and ANGPTL4 expression levels were not associated with donors’ insulin sensitivity (P > 0·2, all). Treatment of myotubes with a selective high-affinity PPARδ agonist (GW501516) did not change mean PPARD, but enhanced mean PDK4 and ANGPTL4 expression 13- and 16-fold, respectively (P < 0·0001, both). The individual PDK4 and ANGPTL4 expression levels reached upon GW501516 treatment were associated with donors’ insulin sensitivity neither (P > 0·2, both). However, GW501516-mediated fold increments in PDK4 and ANGPTL4 expression, reflecting PPARδ responsiveness, were positively associated with donors’ insulin sensitivity derived from OGTT (P = 0·0182 and P = 0·0231, respectively) and hyperinsulinemic-euglycemic clamp (P = 0·0046 and P = 0·0258, respectively).
Conclusions Using a highly selective pharmacological tool, we show here that the individual responsiveness of human muscle cell PPARδ, rather than the absolute PPARD expression level, represents a major determinant of insulin sensitivity.